Capricor Therapeutics, Inc. (CAPR) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Cushion ⢠No Revenue ⢠Negative FCF CAPR has a very strong liquidity position with net cash and low leverage, but its lack of revenue, sustained losses, and negative cash flow make the current thesis highly dependent on its cash runway and future execution.
Price Behavior
Key Price Behavior Insights: ⢠Higher-Low Trend ⢠Strong Support ⢠Near-Term Resistance Support Level: $34 to $34.50 Resistance Level: $35.27 CAPR has been in a constructive uptrend over the last month, holding higher highs/higher lows above $34 support, but it may need a short consolidation before challenging $35.27 resistance.
Sentiment & News
Key News Insights: ⢠Price breakout ⢠Insider sales ⢠Momentum caution Capricor Therapeutics saw a short-term breakout above its 50-day average, but the move was tempered by significant insider selling near the $30â$31 level.
AI Summary
CAPR has shifted from a speculative biotech story to a near-term FDA catalyst with real upside, but the investment now hinges on whether the resubmitted BLA fully resolves the prior efficacy and CMC issues by the PDUFA date; the strong cash position buys time, but it does not reduce the stock's binary regulatory risk.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSâCoVâ2ârelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDâ19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |